Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

Published:2017-12-13 Issue:3 Volume:17 Page:671-676
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Sakamuri Divya,Glitza Isabella C.,Betancourt Cuellar Sonia L.,Subbiah Vivek,Fu Siqing,Tsimberidou Apostolia M.,Wheler Jennifer J.,Hong David S.,Naing Aung,Falchook Gerald S.,Fanale Michelle A.,Cabanillas Maria E.,Janku Filip

Funder

National Center for Advancing Translational Sciences

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies;Cancer Communications;2024-07-28

2. Immunological Drug–Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies;Chemical Research in Toxicology;2024-06-24

3. Immune-related dermatological adverse events of antitumor immunotherapy with PD-1, PD-L1, CTLA-4 inhibitors;Russian Journal of Skin and Venereal Diseases;2024-05-14

4. Versatile tissue‐injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeutics;Bioengineering & Translational Medicine;2024-04-15

5. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways;Cancer Cell International;2024-03-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP